文献速递食管胃疾病与幽门螺杆菌

粪菌移植治疗复发性艰难梭菌感染优于非达霉素

Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
PubMed 文献 · Gastroenterology · 2019-01-02

这项单中心随机试验纳入64例复发性艰难梭菌感染成人,比较粪菌移植(FMTv)、非达霉素和万古霉素的疗效。FMTv组达到临床缓解且毒素检测阴性的比例为71%,高于非达霉素组的33%和万古霉素组的19%。

要点

  • FMTv组临床缓解且毒素阴性的比例为71%,非达霉素组为33%,万古霉素组为19%。
  • FMTv组临床缓解率为92%,非达霉素组为42%,万古霉素组为19%。
  • 初治FMTv与挽救性FMTv的结果无显著差异,有1例严重不良事件可能与FMTv相关。

核心结论

  • 在复发性艰难梭菌感染患者中,FMTv在临床和微生物学缓解或单独临床缓解终点上优于非达霉素或万古霉素。

研究设计与样本

  • 单中心随机试验,纳入2016年4月5日至2018年6月10日在丹麦一家胃肠病诊所就诊的连续成人复发性艰难梭菌感染患者,共64例。
  • 患者随机分为FMTv组(万古霉素125 mg每日4次×4-10天后经结肠镜或鼻空肠管行FMT,n=24)、非达霉素组(200 mg每日2次×10天,n=24)或万古霉素组(125 mg每日4次×10天,n=16)。
  • 主要终点为分配治疗后8周临床缓解且艰难梭菌毒素聚合酶链反应检测阴性。

主要发现

  • 临床缓解且毒素检测阴性:FMTv组17例(71%)vs 非达霉素组8例(33%),P=.009;FMTv组vs 万古霉素组3例(19%),P=.001;非达霉素组vs 万古霉素组P=.31。
  • 临床缓解:FMTv组22例(92%)vs 非达霉素组10例(42%),P=.0002;FMTv组vs 万古霉素组3例(19%),P<.0001;非达霉素组vs 万古霉素组P=.13。
  • 初治FMTv与挽救性FMTv的结果无显著差异。
  • 有1例严重不良事件可能与FMTv相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is recommended for treatment of recurrent Clostridium difficile infection (rCDI). We performed a single-center randomized trial to compare the effects of FMT with those of fidaxomicin and vancomycin. METHODS: We studied consecutive adults with rCDI seen at a gastroenterology clinic in Denmark from April 5, 2016 through June 10, 2018. Patients were randomly assigned to a group that received FMT, applied by colonoscopy or nasojejunal tube, after 4-10 days of vancomycin (125 mg 4 times daily; FMTv; n = 24), 10 days of fidaxomicin (200 mg twice daily; n = 24), or 10 days of vancomycin (125 mg 4 times daily; n = 16). Patients who had rCDI after this course of treatment and patients who could not be randomly assigned to groups were offered rescue FMTv. The primary outcome was combined clinical resolution and a negative result from a polymerase chain reaction test for Clostridium difficile (CD) toxin 8 weeks after the allocated treatment. Secondary end points included clinical resolution at week 8. RESULTS: All 64 patients received their assigned treatment. The combination of clinical resolution and negative results from the test for CD were observed in 17 patients given FMTv (71%), 8 patients given fidaxomicin (33%), and 3 patients given vancomycin (19%; P = .009 for FMTv vs fidaxomicin; P = .001 for FMTv vs vancomycin; P = .31 for fidaxomicin vs vancomycin). Clinical resolution was observed in 22 patients given FMTv (92%), 10 patients given fidaxomicin (42%), and 3 patients given vancomycin (19%; P = .0002; P < .0001; P = .13). Results did not differ significantly between patients who received FMTv as their initial therapy and patients who received rescue FMTv. There was 1 serious adverse event that might have been related to FMTv. CONCLUSIONS: In a randomized trial of patients with rCDI, we found the FMTv combination superior to fidaxomicin or vancomycin based on end points of clinical and microbiological resolution or clinical resolution alone. ClinicalTrials.gov, number NCT02743234; EudraCT, j.no 2015-003004-24.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology. 2019. PMID: 30610862. doi:10.1053/j.gastro.2018.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。